论文部分内容阅读
目的:观测通脉新复方对系膜增生性肾炎(MsPGN)病理学改变的影响。方法:采用抗胸腺抗血清(ATS)制备大鼠MsPGN肾炎模型及行疲劳游泳致气虚血瘀证模型,分别ig给药高、中、低剂量(1.2,0.6,0.3 g.kg-1)通脉新复方4周。4周后进行肾组织病理学检查、免疫荧光检测IgG以及免疫组化法测定肾小球内细胞核增殖抗原PCNA的表达。结果:通脉新复方能抑制肾小球系膜增生,降低系膜区基质占毛细血管丛面积的百分比,减少大鼠肾脏系膜区IgG沉积,显著降低肾小球内PCNA阳性细胞数。结论:通脉新复方能改善系膜增生性肾炎大鼠模型肾组织病理损伤。
Objective: To observe the effect of Tongmaixin compound on pathological changes of mesangial proliferative nephritis (MsPGN). METHODS: The rat model of MsPGN nephritis was prepared by anti-thymus antiserum (ATS) and the model of fatigue-induced swimming-induced qi-deficiency and blood-stasis syndrome was administered. The high-, medium-, and low-dose (1.2, 0.6, 0.3 g.kg-1) doses were administered ig respectively. Pulse new compound for 4 weeks. After 4 weeks, renal histopathological examination, immunofluorescence detection of IgG and immunohistochemistry were performed to determine the expression of proliferating cell nuclear antigen (PCNA) in the glomerulus. Results: Tongmaixin compound can inhibit mesangial proliferation, reduce the percentage of mesangial area matrix accounting for capillary plexus area, reduce IgG deposition in rat mesangial area, and significantly reduce the number of PCNA positive cells in glomerulus. Conclusion: Tongmaixin compound can improve the pathological damage of kidney in rat model of mesangial proliferative nephritis.